ArticleCancers2023

MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study.

Margherita Turinetto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.